Rasch Analysis of the Motor Function Measure in Patients with Congenital Muscle Dystrophy and Congenital Myopathy
Vuillerot C, Rippert P, Kinet V, Renders A, Jain M, Waite M, Glanzman AM, Girardot F, Hamroun D, Iwaz J, Ecochard R, Quijano-Roy S, Bérard C, Poirot I, Bönnemann CG; CDM MFM study group.
Arch Phys Med Rehabil. 2014. 57(9-10):587-99.
The main goal of the study is to provide a valid outcome measure in order to monitor treatment effects in patients with congenital disorders of muscle.
289 patients, aged 5 to 77 years old, were enrolled and the three domains of the MFM were examined using a Rasch analysis.
The original 32-item MFM did not fit the Rasch model expectations enough in neither of its domains. Switching from a four- (0,1,2,3) to a three-category response scale (0,1,2) restored response order in 16 items. Various additional checks suggested the removal of seven items. The resulting 25-item MFM demonstrated a good fit to the Rasch model. Domain 1 was well targeted to the whole severity spectrum whereas Domains 2 and 3 were better targeted to severe cases. The reliability coefficients of the Rasch MFM-25 suggested sufficient ability for each summed score to distinguish between patient groups.
Keywords: Rasch analysis, congenital muscular dystrophy, congenital myopathy, motor function assessment, outcome measure
Articles dans les revues scientifiques
The Use of the Gait Profile Score and Gait Variable Score in Individuals With Duchenne Muscular Dystrophy
de Souza MA, Cezarani A, Lizzi EAD, Davoli GBQ, Mattiello SM, Jones R, Mattiello-Sverzut AC J Biomech. 2020. 98, 109485. Study of the applicability of the Gait Deviation Index (GDI) and the Gait Profile Score (GPS) in patients with duchenne Muscular Dystrophy, using...
Analysis of Different Device Interactions in a Virtual Reality Task in Individuals With Duchenne Muscular Dystrophy-A Randomized Controlled Trial
de Freitas BL, da Silva TD, Crocetta TB, Massetti T, de Araújo LV, Coe S, Dawes H, Caromano FA, Monteiro CBM. Front Neurol. 2019 Jan 29;10:24. The aim of the study was to compare performance of patients with Duchenne Muscular Dystrophy to perform a virtual task using...
Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy.
Nagy S, Schädelin S, Hafner P, Bonati U, Scherrer D, Ebi S, Schmidt S, Orsini AL, Bieri O, Fischer D. Muscle Nerve. 2020. 61(1), 63-68. In this retrospective study, the longitudinal reliability of clinical and radiological endpoints in 29 ambulant patients with DMD...
Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies.
Jain MS, Meilleur K, Kim E, Norato G, Waite M, Nelson L, McGuire M, Duong T, Keller K, Lott DJ, Glanzman A, Rose K, Main M, Fiorini C, Chrismer I, Linton M, Punjabi M, Elliott J, Tounkara F, Vasavada R, Logaraj R, Winkert J, Donkervoort S, Leach M, Dastgir J, Hynan L,...
Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
Hafner P, Bonati U, Klein A, Rubino D, Gocheva V, Schmidt S, Schroeder J, Bernert G, Laugel V, Steinlin M, Capone A, Gloor M, Bieri O, Hemkens LG, Speich B, Zumbrunn T, Gueven N, Fischer D. JAMA Netw Open. 2019. 2;2(10):e1914171. Results of a single-center randomized...
Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D. Trials. 2019. 20(1), 637. Protocol of a multicenter, randomized, double-blind, placebo-controlled phase III trial study aiming to demonstrate safety and efficacy of tamoxifen over placebo in...